Literature DB >> 8545224

Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Kaiser Permanente Measles Vaccine Trial Team.

L E Markowitz1, P Albrecht, P Rhodes, R Demonteverde, E Swint, E F Maes, C Powell, P A Patriarca.   

Abstract

OBJECTIVES: In the United States, younger women are more likely to have immunity to measles from vaccination and are less likely to have been exposed to the wild virus than are older women. To evaluate changes in measles antibody titers in women in the United States and children's responses to measles vaccination, we analyzed data from a measles vaccine trial.
METHODS: Sera collected from children before vaccination at 6, 9, or 12 months of age and from their mothers were assayed for measles antibodies by plaque reduction neutralization. Responses to vaccination with Merck Sharp & Dohme live measles virus vaccines at 9 months (Attenuvax) and 12 months (M-M-R II) were also analyzed.
RESULTS: Among women born in the United States (n = 614), geometric mean titers (GMTs) of measles antibodies decreased with increasing birth year. For those born before 1957, 1957 through 1963, and after 1963, GMTs were 4798, 2665, and 989, respectively. Among women born outside of the United States (n = 394), there were no differences in GMTs by year of birth. Children of younger women born in the United States were less likely than those of older women to be seropositive at 6, 9, or 12 months. The response to the vaccines varied by maternal birth year for children of women born in the United States. Among 9-month-old children, 93% of those whose mothers were born after 1963 responded, compared with 77% and 60% of those whose mothers were born in 1957 through 1963 and before 1957, respectively. Among 12-month-old children, 98% of those born to the youngest mothers responded, compared with 90% and 83% of those whose mothers were born in 1957 through 1963 and before 1957. The responses of children of women born outside of the United States were not associated with maternal year of birth.
CONCLUSIONS: An increasing proportion of children in the United States will respond to the measles vaccine at younger ages because of lower levels of passively acquired maternal measles antibodies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8545224

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  14 in total

1.  Knowledge of the Tuskegee study and its impact on the willingness to participate in medical research studies.

Authors:  V L Shavers; C F Lynch; L F Burmeister
Journal:  J Natl Med Assoc       Date:  2000-12       Impact factor: 1.798

2.  Neonatal DNA immunization with a plasmid encoding an internal viral protein is effective in the presence of maternal antibodies and protects against subsequent viral challenge.

Authors:  D E Hassett; J Zhang; J L Whitton
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 3.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

4.  Safety and immunogenicity of early measles vaccination in children born to HIV-infected mothers in the United States: results of Pediatric AIDS Clinical Trials Group (PACTG) protocol 225.

Authors:  Sulachni Chandwani; Judy Beeler; Hong Li; Susette Audet; Betsy Smith; John Moye; David Nalin; Keith Krasinski
Journal:  J Infect Dis       Date:  2011-07       Impact factor: 5.226

5.  Protective levels of polysaccharide-specific maternal antibodies may enhance the immune response elicited by pneumococcal conjugates in neonatal and infant mice.

Authors:  Margret Y Richter; Havard Jakobsen; Jean-François Haeuw; Ultan F Power; Ingileif Jonsdottir
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

Review 6.  Active immunization in the United States: developments over the past decade.

Authors:  P H Dennehy
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

7.  Prevention of measles, mumps and rubella: 40 years of global experience with M-M-RII.

Authors:  Barbara J Kuter; Gary S Marshall; Jaime Fergie; Elvira Schmidt; Manjiri Pawaskar
Journal:  Hum Vaccin Immunother       Date:  2022-02-07       Impact factor: 3.452

8.  Kinetics of decline of maternal measles virus-neutralizing antibodies in sera of infants in France in 2006.

Authors:  Arnaud Gagneur; Didier Pinquier; Marie Aubert; Laurent Balu; Olivier Brissaud; Loïc De Pontual; Christèle Gras Le Guen; Isabelle Hau-Rainsard; Olivier Mory; Georges Picherot; Jean-Louis Stephan; Bernard Cohen; Evelyne Caulin; Benoît Soubeyrand; Philippe Reinert
Journal:  Clin Vaccine Immunol       Date:  2008-09-24

9.  Measles humoral and cell-mediated immunity in children aged 5-10 years after primary measles immunization administered at 6 or 9 months of age.

Authors:  Hayley A Gans; Linda L Yasukawa; Phillip Sung; Barbara Sullivan; Ross DeHovitz; Susette Audet; Judy Beeler; Ann M Arvin
Journal:  J Infect Dis       Date:  2013-01-08       Impact factor: 5.226

10.  High Concentrations of Measles Neutralizing Antibodies and High-Avidity Measles IgG Accurately Identify Measles Reinfection Cases.

Authors:  Sun B Sowers; Jennifer S Rota; Carole J Hickman; Sara Mercader; Susan Redd; Rebecca J McNall; Nobia Williams; Marcia McGrew; M Laura Walls; Paul A Rota; William J Bellini
Journal:  Clin Vaccine Immunol       Date:  2016-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.